CCA
WST icon

Catalyst Capital Advisors’s West Pharmaceutical WST Stock Holding History

Catalyst Capital Advisors’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,690
Closed -$476K – 408
2021
Q1 		$476K Hold
1,690
– – 0.03% 181
2020
Q4 		$479K Hold
1,690
– – 0.03% 179
2020
Q3 		$465K Sell
1,690
-310
-16% -$82K 0.03% 177
2020
Q2 		$454K Buy
+2,000
New +$393K 0.02% 174

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Catalyst Capital Advisors's WST Position: Q2 2021 in Review

Catalyst Capital Advisors sold out of West Pharmaceutical (WST) in Q2 2021, closing a stake of 1,690 shares — an estimated $476K sold.

Catalyst Capital Advisors first reported a position in WST in Q2 2020 and held it in 4 quarters. The position peaked at $479K in Q4 2020. 640 funds tracked by Wall St. Rank hold WST as of Q2 2021.

  • Catalyst Capital Advisors reported no remaining West Pharmaceutical position as of Q2 2021 after selling out during the quarter.
  • Catalyst Capital Advisors sold 1,690 West Pharmaceutical shares in Q2 2021, an estimated $476K.
  • Catalyst Capital Advisors first reported a position in West Pharmaceutical in Q2 2020 and held it in 4 quarters.
  • Catalyst Capital Advisors's West Pharmaceutical position peaked at $479K in Q4 2020.
  • 640 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2021.

Based on Catalyst Capital Advisors's 13F filing for Q2 2021, filed 6 Aug 2021.